Maverick Capital’s Quest Diagnostics DGX Stock Holding History

Maverick Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$540K	Sell	2,756 -21,139	-88%	-$4.11M	0.01%	218
2025 Q4	$4.15M	Buy	23,895 +5,717	+31%	+$1.04M	0.04%	97
2025 Q3	$3.46M	Buy	+18,178	New	+$3.23M	0.05%	116
2023 Q3	–	Sell	-8,046	Closed	-$1.13M	–	365
2023 Q2	$1.13M	Buy	8,046 +2,503	+45%	+$345K	0.02%	154
2023 Q1	$784K	Buy	+5,543	New	+$793K	0.02%	180
2021 Q2	–	Sell	-2,441	Closed	-$313K	–	714
2021 Q1	$313K	Buy	2,441 +1,813	+289%	+$223K	﹤0.01%	435
2020 Q4	$75K	Buy	+628	New	+$76.6K	﹤0.01%	602
2016 Q4	–	Sell	-37,510	Closed	-$3.17M	–	131
2016 Q3	$3.17M	Buy	+37,510	New	+$3.15M	0.04%	56

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Maverick Capital's DGX Position: Q1 2026 in Review

Maverick Capital reduced its Quest Diagnostics (DGX) stake by 88% in Q1 2026, selling an estimated $4.11M and leaving 2,756 shares worth $540K. The position accounts for 0.01% of the portfolio, ranked #218.

Maverick Capital first reported a position in DGX in Q3 2016 and has held it in 8 quarters since. The position peaked at $4.15M in Q4 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Maverick Capital held 2,756 shares of Quest Diagnostics worth $540K as of Q1 2026.
Maverick Capital sold 21,139 Quest Diagnostics shares in Q1 2026, an estimated $4.11M.
Quest Diagnostics made up 0.01% of Maverick Capital's portfolio in Q1 2026, its #218 holding.
Maverick Capital first reported a position in Quest Diagnostics in Q3 2016 and has held it in 8 quarters since.
Maverick Capital's Quest Diagnostics position peaked at $4.15M in Q4 2025.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Maverick Capital's 13F filing for Q1 2026, filed 15 May 2026.